Secondhand Tobacco Smoke and Cardiovascular Disease
Occult Cardiovascular Disease With Chronic Exposure to Secondhand Tobacco Smoke
University of California, San Francisco
100 participants
Mar 30, 2021
INTERVENTIONAL
Conditions
Summary
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
50 mg tablets taken orally
Tablets taken orally
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04715568